CN104302284A - 用于缓解尿频的延长释放制剂及其使用方法 - Google Patents

用于缓解尿频的延长释放制剂及其使用方法 Download PDF

Info

Publication number
CN104302284A
CN104302284A CN201380015062.3A CN201380015062A CN104302284A CN 104302284 A CN104302284 A CN 104302284A CN 201380015062 A CN201380015062 A CN 201380015062A CN 104302284 A CN104302284 A CN 104302284A
Authority
CN
China
Prior art keywords
active component
analgesics
release
formulated
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015062.3A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·A·迪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Priority to CN201710373440.5A priority Critical patent/CN107157991A/zh
Publication of CN104302284A publication Critical patent/CN104302284A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380015062.3A 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法 Pending CN104302284A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710373440.5A CN107157991A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/424,000 2012-03-19
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
PCT/US2013/030901 WO2013142197A1 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710373440.5A Division CN107157991A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法

Publications (1)

Publication Number Publication Date
CN104302284A true CN104302284A (zh) 2015-01-21

Family

ID=49223209

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201380015062.3A Pending CN104302284A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法
CN201710373440.5A Pending CN107157991A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法
CN201711086139.2A Pending CN107789626A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法
CN201380015025.2A Pending CN104321056A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201710373440.5A Pending CN107157991A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法
CN201711086139.2A Pending CN107789626A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法
CN201380015025.2A Pending CN104321056A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法

Country Status (15)

Country Link
EP (2) EP2827852A4 (enExample)
JP (5) JP2015510928A (enExample)
KR (4) KR20140134333A (enExample)
CN (4) CN104302284A (enExample)
AU (4) AU2013235518B2 (enExample)
BR (2) BR112014020271A8 (enExample)
CA (2) CA2866853A1 (enExample)
HK (3) HK1204553A1 (enExample)
MX (3) MX2014011128A (enExample)
MY (2) MY174090A (enExample)
NZ (6) NZ712594A (enExample)
RU (3) RU2669565C2 (enExample)
SG (2) SG11201500408VA (enExample)
WO (2) WO2013142197A1 (enExample)
ZA (2) ZA201405862B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108391420A (zh) * 2015-09-30 2018-08-10 韦尔斯利医药有限公司 用于减少排尿频率的组合物及其制备方法和应用
CN108430465A (zh) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 用于缓解尿频的组合物、其制造方法和用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
JP2017516832A (ja) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
CA2967390A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置
JP2019031556A (ja) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040942A1 (en) * 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
KR101113005B1 (ko) * 2003-03-21 2012-02-24 맥네일-피피씨, 인코포레이티드 비-스테로이드계 항염증성 약물 투여법
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
JP5173190B2 (ja) * 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CN101505746A (zh) * 2005-06-17 2009-08-12 迪纳米斯治疗公司 炎症的治疗方法
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
RU2435610C2 (ru) * 2005-09-02 2011-12-10 Теравида, Инк. Терапия для лечения заболевания
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SONG Y. S. ET AL: "Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study", 《INTENATIONAL UROLOGY AND NEPHROLOGY》, vol. 39, 31 December 2007 (2007-12-31), pages 1147 - 1152, XP019557635, DOI: doi:10.1007/s11255-007-9206-x *
YOKOYAMA, O等: "Zolpidem Increases Bladder Capacity and Decreases Urine Excretion in Rats", 《NEUROUROLOGY AND URODYNAMICS》, vol. 29, no. 4, 31 December 2010 (2010-12-31), pages 587 - 591, XP002743174, DOI: doi:10.1002/nau.20797 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108391420A (zh) * 2015-09-30 2018-08-10 韦尔斯利医药有限公司 用于减少排尿频率的组合物及其制备方法和应用
CN108430465A (zh) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 用于缓解尿频的组合物、其制造方法和用途

Also Published As

Publication number Publication date
NZ714288A (en) 2016-12-23
AU2017203246B2 (en) 2018-10-18
AU2013235518A2 (en) 2014-10-09
JP2015510928A (ja) 2015-04-13
CN104321056A (zh) 2015-01-28
NZ628079A (en) 2016-05-27
NZ714662A (en) 2016-08-26
AU2017203139A1 (en) 2017-06-01
HK1204553A1 (en) 2015-11-27
MY175764A (en) 2020-07-08
AU2017203246A1 (en) 2017-06-08
JP2015510936A (ja) 2015-04-13
JP2018138602A (ja) 2018-09-06
JP2016172752A (ja) 2016-09-29
MX2019008817A (es) 2019-09-26
AU2013235518A1 (en) 2014-09-25
CN107789626A (zh) 2018-03-13
BR112014020113A2 (enExample) 2017-06-20
RU2669565C2 (ru) 2018-10-12
KR20140134333A (ko) 2014-11-21
MX2014011128A (es) 2015-08-10
KR20190003840A (ko) 2019-01-09
CA2866853A1 (en) 2013-07-26
NZ718163A (en) 2017-09-29
AU2013235507B2 (en) 2017-03-23
EP2827852A4 (en) 2016-03-02
AU2013235507A1 (en) 2014-08-21
EP2827851A4 (en) 2015-10-14
CA2866755A1 (en) 2013-09-26
SG11201500409SA (en) 2015-03-30
SG11201500408VA (en) 2015-03-30
HK1243921A1 (zh) 2018-07-27
NZ630471A (en) 2016-04-29
MX2014011129A (es) 2015-08-10
RU2014142066A (ru) 2016-05-10
NZ712594A (en) 2016-09-30
EP2827851A1 (en) 2015-01-28
RU2016133305A3 (enExample) 2018-12-10
RU2014142025A (ru) 2016-05-10
BR112014020271A8 (pt) 2017-07-11
WO2013142274A1 (en) 2013-09-26
CN107157991A (zh) 2017-09-15
RU2599017C2 (ru) 2016-10-10
KR20170015537A (ko) 2017-02-08
HK1251469A1 (zh) 2019-02-01
AU2017203139B2 (en) 2018-07-19
WO2013142197A1 (en) 2013-09-26
ZA201406146B (en) 2016-08-31
BR112014020113A8 (pt) 2017-07-11
RU2016133305A (ru) 2018-12-10
BR112014020271A2 (enExample) 2017-06-20
KR20140134284A (ko) 2014-11-21
AU2013235518B2 (en) 2017-03-02
ZA201405862B (en) 2016-08-31
EP2827852A1 (en) 2015-01-28
MY174090A (en) 2020-03-09
JP2018024693A (ja) 2018-02-15

Similar Documents

Publication Publication Date Title
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AU2017203418B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CN107157991A (zh) 用于缓解尿频的延长释放制剂及其使用方法
JP2018039831A (ja) 排尿頻度を減少させるための医薬製剤およびその使用の方法
US9415048B2 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
HK1248549A1 (zh) 用於缓解尿频的延长释放制剂及其使用方法
CN108391420A (zh) 用于减少排尿频率的组合物及其制备方法和应用
CN108135870A (zh) 延缓、延迟和立即释放型制剂及其制造方法和用途
TWI587879B (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法
CN108289891A (zh) 缓解尿频的组合物，其制造方法和应用
CN108430465A (zh) 用于缓解尿频的组合物、其制造方法和用途
HK1259770A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
HK1259497A1 (zh) 用於减少排尿频率的组合物及其制备方法和应用
HK1187241A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150121

RJ01 Rejection of invention patent application after publication